<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Acronyms COVID-19, coronavirus disease 2019 CPT, convalescent plasma therapy CQ," exact="chloroquine" post="EC50, half-maximal effective concentration HCQ, hydroxychloroquine ICU, intensive care"/>
 <result pre="convalescent plasma therapy CQ, chloroquine EC50, half-maximal effective concentration HCQ," exact="hydroxychloroquine" post="ICU, intensive care unit IL-6, interleukin 6 JAK, Janus"/>
 <result pre="14, 15, 16, 17, 18, 19Clinical trial: 20, 21, 22" exact="Adenosine" post="analogue that causes termination of RNA synthesis Antiviral Favipiravir"/>
 <result pre="inhibitor/selective inhibitors of Janus kinases/modulation of immune responses Anti-inflammatory Chloroquine," exact="hydroxychloroquine" post="Preclinical: 77, 78, 98, 99Case series: 91Cohort: 81, 82,"/>
 <result pre="distress syndrome coronavirusÂ 2. bNonâ€&quot;peer-reviewed publications. Remdesivir Remdesivir is an" exact="adenosine" post="analogue developed to treat Ebola. Its effects derive from"/>
 <result pre="its usefulness in treating COVID-19 and its widespread use with" exact="ribavirin" post="in the management of COVID-19 in China. The reported"/>
 <result pre="did a randomized trial in 22 patients comparing LPV/RTV with" exact="chloroquine" post="(CQ).40 A study of LPV/RTV pharmacokinetic properties in 8"/>
 <result pre="of COVID-19. Janus kinase (JAK) inhibitors such as baricitinib and" exact="ruxolitinib" post="are also being considered for treating COVID-19â€&quot;associated cytokine storm."/>
 <result pre="of 10056 and 8557 patients receiving tocilizumab plus LPV/RTV or" exact="hydroxychloroquine" post="(HCQ) compared with LPV/RTV or HCQ alone, respectively, found"/>
 <result pre="randomized trial of a different JAK inhibitor, ruxolitinib, patients receiving" exact="ruxolitinib" post="had numerically faster, but not statistically significant (P=.147), time"/>
 <result pre="58% decline in inflammation scores 7 days after treatment with" exact="ruxolitinib" post="(P&amp;lt;.01) and 76% of patients had clinical improvement on"/>
 <result pre="stay.67 However, a 6425-patient open-label RCT of low- to moderate-dose" exact="dexamethasone" post="reported reductions in 28-day mortality in one-third of patients"/>
 <result pre="ventilation (rate ratio, 0.82; 95% confidence interval, 0.72 to 0.94).68" exact="Chloroquine" post="and Hydroxychloroquine Hydroxychloroquine and CQ are quinine analogues that"/>
 <result pre="ratio, 0.82; 95% confidence interval, 0.72 to 0.94).68 Chloroquine and" exact="Hydroxychloroquine" post="Hydroxychloroquine and CQ are quinine analogues that have been"/>
 <result pre="0.82; 95% confidence interval, 0.72 to 0.94).68 Chloroquine and Hydroxychloroquine" exact="Hydroxychloroquine" post="and CQ are quinine analogues that have been widely"/>
 <result pre="0.72 to 0.94).68 Chloroquine and Hydroxychloroquine Hydroxychloroquine and CQ are" exact="quinine" post="analogues that have been widely used in the treatment"/>
 <result pre="0.4 to 2.1)82 who received HCQ or HCQ added to" exact="azithromycin" post="or who were unexposed to HCQ. Likewise, in a"/>
 <result pre="1.04, 95% confidence interval, 0.82 to 1.32)83 or HCQ and" exact="azithromycin" post="use and mortality.84 The first double-blind, RCT of postexposure"/>
 <result pre="12.5% of control patients (P&amp;lt;.001).86 Although a follow-up study of" exact="azithromycin" post="combined with HCQ in 80 additional French patients with"/>
 <result pre="corrected QT measurements greater than 500 ms after HCQ plus" exact="azithromycin" post="treatment.97 One arm of a double-blind randomized trial of"/>
 <result pre="resultant pulmonary inflammation and edema118 as well as evaluation of" exact="ivermectin" post="based on its inÂ vitro antiâ€&quot;SARS-CoV-2 effects.119TableÂ 2 Clinical"/>
 <result pre="None 48 (75) Single 1 (2) Multi 15 (23) Chloroquine," exact="hydroxychloroquine" post="134 Global 123 (92) None 65 (49) Single 10"/>
 <result pre="National Institutes of Healthâ€™s Outcomes Related to COVID-19 treated with" exact="hydroxychloroquine" post="among in-patients with symptomatic Disease study (ORCHID) was halted"/>
 <result pre="Oxford SoCÂ + LPV/RTVSoCÂ + IFN Î²-1aSoCÂ + HCQSoCÂ +" exact="dexamethasone" post="SoC Phase II/III, adaptive, open-label RCT â‰¥18 y and"/>
 <result pre="d of randomizationHospital length of stayNumber of patients needing ventilation" exact="Hydroxychloroquine" post="Versus Placebo in COVID-19 Patients at Risk for Severe"/>
 <result pre="length of stay COVID-19Â = coronavirus disease 2019; CQ/HCQÂ =" exact="chloroquine" post="or hydroxychloroquine; FiO2Â = fraction of inspired oxygen; ICUÂ"/>
 <result pre="clinical efficacy. The preliminary results of the low- to moderate-dose" exact="dexamethasone" post="arm of the Randomised Evaluation of COVID-19 Therapy (RECOVERY)"/>
 <result pre="such as cancer, obesity, Alzheimer disease, diabetes, or opioid and" exact="alcohol" post="addiction. The COVID-19 pandemic is a formidable health care"/>
 <result pre="MERS-CoV infectionProc Natl Acad Sci U S A1171220206771677632054787 12WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
 <result pre="ahead of print April 15, 2020]medRxivhttps://doi.org/10.1101/2020.03.17.20037432 27KimU.J.WonE.J.KeeS.J.JungS.I.JangH.C.Combination therapy with lopinavir/ritonavir," exact="ribavirin" post="and interferon-Î± for Middle East respiratory syndromeAntivir Ther215201645545926492219 28SpanakisN.TsiodrasS.HaagmansB.L.Virological"/>
 <result pre="Med Pharmacol Sci24620203390339632271456 35HungI.F.N.LungK.C.TsoE.Y.K.Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="10.1016/j.medj.2020.04.001/S2666-6340(20)30001-5. 40HuangM.TangT.PangP.Treating COVID-19 with chloroquineJÂ Mol Cell Biol124202032232532236562 41SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of" exact="lopinavir" post="and ritonavir in patients hospitalized with coronavirus disease 2019"/>
 <result pre="COVID-19 with chloroquineJÂ Mol Cell Biol124202032232532236562 41SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and" exact="ritonavir" post="in patients hospitalized with coronavirus disease 2019 (COVID-19) [published"/>
 <result pre="trialJÂ Allergy Clin Immunol14612020137146.e14332470486 66La RosÃ©eF.BremerH.C.GehrkeI.The Janus kinase 1/2 inhibitor" exact="ruxolitinib" post="in COVID-19 with severe systemic hyperinflammationLeukemia34720201805181532518419 67LuS.ZhouQ.HuangL.Effectiveness and safety"/>
 <result pre="antiviral agentsProc Natl Acad Sci U S A7861981360536096115382 71ShimizuY.YamamotoS.HommaM.IshidaN.Effect of" exact="chloroquine" post="on the growth of animal virusesArch Gesamte Virusforsch3611972931044335025 72KeyaertsE.VijgenL.MaesP.NeytsJ.Van"/>
 <result pre="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 73TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antiviral Res177202010476232147496 74PatonN.I.LeeL.XuY.Chloroquine for influenza prevention: a randomised,"/>
 <result pre="placebo controlled trialLancet Infect Dis119201167768321550310 75TricouV.MinhN.N.VanT.P.AÂ randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adults [published"/>
 <result pre="2012;6(6)]PLoS Negl Trop Dis482010e78520706626 76De LamballerieX.BoissonV.ReynierJ.C.On chikungunya acute infection and" exact="chloroquine" post="treatmentVector Borne jDis862008837840 77LiuJ.CaoR.XuM.Hydroxychloroquine, a less toxic derivative of"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis7115202073273932150618 79ChenJ.LiuD.LiuL.AÂ pilot study of" exact="hydroxychloroquine" post="in treatment of patients with common coronavirus disease-19 (COVID-19)JÂ"/>
 <result pre="coronavirus disease 2019: open label, randomised controlled trialBMJ3692020m184932409561 81MagagnoliJ.NarendranS.PereiraF.Outcomes of" exact="hydroxychloroquine" post="usage in United States veterans hospitalized with COVID-19 [published"/>
 <result pre="online ahead of print April 21, 2020]medRxivhttps://doi.org/10.1101/2020.04.16.20065920 82MahÃ©vasM.TranV.T.RoumierM.Clinical efficacy of" exact="hydroxychloroquine" post="in patients with covid-19 pneumonia who require oxygen: observational"/>
 <result pre="observational comparative study using routine care dataBMJ3692020m184432409486 83GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association"/>
 <result pre="patients with Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association of treatment with" exact="hydroxychloroquine" post="or azithromycin with in-hospital mortality in patients with COVID-19"/>
 <result pre="Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association of treatment with hydroxychloroquine or" exact="azithromycin" post="with in-hospital mortality in patients with COVID-19 in New"/>
 <result pre="with COVID-19 in New York stateJAMA3232420202493250232392282 85BoulwareD.R.PullenM.F.BangdiwalaA.S.AÂ randomized trial of" exact="hydroxychloroquine" post="as postexposure prophylaxis for Covid-19NÂ Engl J Med3836202051752532492293 86GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine"/>
 <result pre="as postexposure prophylaxis for Covid-19NÂ Engl J Med3836202051752532492293 86GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="Antimicrob Agents561202010594932205204 87GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
 <result pre="87GautretP.LagierJ.-C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
 <result pre="up: an observational studyTravel Med Infect Dis34202010166332289548 88DahleyD.GatesS.OrrisT.Statistical review of" exact="hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
 <result pre="observational studyTravel Med Infect Dis34202010166332289548 88DahleyD.GatesS.OrrisT.Statistical review of hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="online ahead of print March 2020]ResearchGatehttps://doi.org/10.13140/RG.2.2.24669.36325 90Statement on IJAA paper:" exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
 <result pre="of print March 2020]ResearchGatehttps://doi.org/10.13140/RG.2.2.24669.36325 90Statement on IJAA paper: Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed Mal"/>
 <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed Mal Infect504202038432240719 92MillionM.LagierJ.-C.GautretP.Early"/>
 <result pre="COVID-19 infectionMed Mal Infect504202038432240719 92MillionM.LagierJ.-C.GautretP.Early treatment of COVID-19 patients with" exact="hydroxychloroquine" post="and azithromycin: a retrospective analysis of 1061 cases in"/>
 <result pre="cases in Marseille, FranceTravel Med Infect Dis35202010173832387409 93YuB.LiC.ChenP.Low dose of" exact="hydroxychloroquine" post="reduces fatality of critically ill patients with COVID-19 [published"/>
 <result pre="Sci. June 18, 2020. doi:10.1007/s11427-020-1751-3]Sci China Life Scihttps://doi.org/10.1007/s11427-020-1732-2 94ChenZ.HuJ.ZhangZ.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
 <result pre="trial [published online ahead of print April 10, 2020]medRxivhttps://doi.org/10.1101/2020.03.22.20040758 95MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED:" exact="Hydroxychloroquine" post="or chloroquine with or without a macrolide for treatment"/>
 <result pre="online ahead of print April 10, 2020]medRxivhttps://doi.org/10.1101/2020.03.22.20040758 95MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED: Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
 <result pre="Therhttps://doi.org/10.1002/cpt.1968 98BorbaM.G.S.ValF.F.A.SampaioV.S.collab: CloroCovid-19 TeamEffect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
 <result pre="online ahead of print June 8, 2020]medRxivhttps://doi.org/10.1101/2020.06.03.20116988 119CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 inÂ vitroAntiviral Res178202010478732251768 120â€œSolidarityâ€�"/>
</results>
